Pinnacle Food Group Limited financials

PFAI CIK 0002032755

Source: EDGAR filings · Built 2026-06-19T01:24:08Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2024FY 2024
Free Cash Flow -5.31M -590.89K 59.33K -107.86K
EBITDA -1.62M 957.81K 1.19M -199.97K
Working Capital 2.91M 999.65K -852.36K
Net Debt 763.43K -523.12K 121.04K
Gross Margin 38.26% 47.28% 61.05% 9.60%
Operating Margin -56.31% 18.69% 49.93% -114.66%
Net Margin -55.78% 8.70% 43.68% -115.70%
Return on Equity (ROE) -45.62% 61.33% -53.63% 7.94%
Return on Assets (ROA) -18.51% 5.11% 24.04%
Current Ratio 2.20× 1.34× 0.71×
Debt-to-Equity 0.41× 0.35× -0.14×
Effective Tax Rate -5.45% 41.08% 19.18%
Cash Conversion Ratio 1.88× 0.71× 0.07× 0.44×
Accruals Ratio 0.16× 0.01× 0.22×
SBC % of Revenue 1.25%
CapEx Coverage -2.08× 0.26× 20.62× -5.25×

Income Statement

Concept FY 2025FY 2024FY 2024FY 2024
Revenues 3.41M 3.29M 2.10M 177.33K
Cost of Revenue 2.11M 1.73M 818.35K 160.30K
Gross Profit 1.31M 1.56M 1.28M 17.03K
Research and Development Expense 171.97K 55.00K 4.38K
Selling, General and Administrative Expense 613.26K 65.12K 2.24K 692
Operating Income (Loss) -1.92M 614.84K 1.05M -203.32K
Income Tax Expense (Benefit) 98.40K 199.50K 217.76K
Net Income (Loss) Attributable to Parent -1.90M 286.14K 917.69K -205.16K

Balance Sheet

Concept FY 2025FY 2024FY 2024FY 2024
Cash and Cash Equivalents, at Carrying Value 942.82K 685.80K 121.37K
Assets, Current 5.32M 3.90M 2.13M
Assets 10.29M 5.60M 3.82M
Long-term Debt 1.02M
Liabilities, Current 2.42M 2.90M 2.98M
Liabilities 3.93M 3.05M 3.26M
Stockholders' Equity Attributable to Parent 4.17M 466.57K -1.71M -2.58M

Cash Flow Statement

Concept FY 2025FY 2024FY 2024FY 2024
Net Cash Provided by (Used in) Operating Activities -3.59M 204.35K 62.35K -90.60K
Payments to Acquire Property, Plant, and Equipment 1.73M 795.23K 3.02K 17.25K
Net Cash Provided by (Used in) Investing Activities -2.76M -1.10M -3.02K -17.25K
Net Cash Provided by (Used in) Financing Activities 6.68M 1.48M 38.89K 93.80K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PFAI CIK 0002032755), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

GGBY

Alpha Investment Inc.

PNW

PINNACLE WEST CAPITAL CORP

ALGS

Aligos Therapeutics, Inc.